Infectious Diseases Department, Université Libre de Bruxelles (ULB), CHU Saint-Pierre, Brussels, Belgium.
Internal Medicine Department, CHU Saint-Pierre, Brussels, Belgium.
Am J Trop Med Hyg. 2018 Apr;98(4):1102-1106. doi: 10.4269/ajtmh.17-0407. Epub 2018 Feb 22.
Emerging evidence indicates that migrants from endemic regions are at risk of delayed presentation of malaria. We report three cases of malaria occurring years after arrival in Europe. All patients were originally from Sub-Saharan Africa. Two subjects had controlled human immunodeficiency virus infection and one was a pregnant woman. We performed a literature review of all published cases of delayed presentation of in migrants and identified 32 additional cases. All cases but one originate from sub-Saharan Africa. There was a median time of 36 months between the last visit to a malaria-endemic country and clinical malaria (range: 3 months to 10 years). Pregnancy was the most frequently reported risk factor (11/35 or 31.4%). Parasitemia was ≤ 0.1% in 38% of cases (11/29 reported), and no death was reported. The underlying possible mechanisms for this delayed presentation in migrants from an endemic area probably include the persistence of submicroscopic parasitemia combined with decaying -specific immunity. Suspicion of delayed malaria should remain high in migrants, mainly from sub-Saharan Africa, even without a recent travel history, especially in those presenting risk factors for impaired parasite clearance or distinct immune responses such as pregnancy and HIV infection. In these patients, new prevention and screening strategies should be studied and blood safety policies adapted.
新出现的证据表明,来自疟疾流行地区的移民有出现疟疾延迟发作的风险。我们报告了三例在抵达欧洲数年后发生的疟疾。所有患者最初都来自撒哈拉以南非洲。两名患者的人类免疫缺陷病毒感染得到控制,一名是孕妇。我们对所有已发表的移民中疟疾延迟发作的病例进行了文献回顾,确定了另外 32 例病例。除一例外,所有病例均来自撒哈拉以南非洲。从最后一次前往疟疾流行国家到出现临床疟疾的时间中位数为 36 个月(范围:3 个月至 10 年)。妊娠是最常报告的危险因素(35 例中的 11 例,占 31.4%)。寄生虫血症在 38%的病例中(29 例中有 11 例报告)≤0.1%,未报告死亡。来自流行地区的移民出现这种延迟发作的潜在可能机制可能包括亚微观寄生虫血症的持续存在,同时伴随着特异性免疫功能的衰退。即使没有近期旅行史,来自撒哈拉以南非洲的移民也应高度怀疑存在疟疾延迟发作,尤其是那些存在寄生虫清除受损或独特免疫反应风险因素的患者,如妊娠和 HIV 感染。在这些患者中,应研究新的预防和筛查策略,并调整血液安全政策。